biostudies-literatureLuo FFundamental Research Funds for the Central Universities, Sun Yat-sen UniversityNatural Science Foundation of Guangdong ProvinceChina Postdoctoral Science FoundationNational Natural Science Foundation of ChinaFostering Program for NSFC Young Applicants (Tulip Talent Training Program) of Sun Yat-sen University Cancer CenterYoung Talents Program of Sun Yat-sen University Cancer Centere14486https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948199biostudies-literatureUnknown13(12)The ubiquitin-editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20-mediated IKK-β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin-NACRT) or capecitabine-only neoadjuvant chemoradiotherapy (non-oxaliplatin-NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin-NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 eAdvanced science (Weinheim, Baden-Wurttemberg, Germany)A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β.PMC12948199YTP-SYSUCC-01042024M75375382 303 80724qnpy2832024A151501301182 203 6492025yfd1882 473 398Chen QXia ZCao JLu ZLuo FLi PLu FZhang RMa WYang YLin CLuo MYang TfalseA20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β.The ubiquitin-editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20-mediated IKK-β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin-NACRT) or capecitabine-only neoadjuvant chemoradiotherapy (non-oxaliplatin-NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin-NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 e2026-01-01T00:00:00Z2026 Feb2026-07-16T22:20:31.506Z2026-07-11T03:12:11.776ZS-EPMC129481994140536710.1002/advs.202514486